Multiple Myeloma

Multiple Myeloma

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

33 Clinical Trials
Multiple Myeloma Phase I Accepting Patients
nct/study# NCT02675452 / 20150161

A Phase I in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma

Learn More
Multiple Myeloma Phase I Accepting Patients
nct/study# NCT04093596 / ALLO-715-101

A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma

Learn More
Multiple Myeloma Phase II Accepting Patients
nct/study# NCT03601078 / BB2121-MM-002

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of BB2121 in Subjects with Multiple Myeloma (KarMMa-2)

Learn More
Multiple Myeloma Phase III Accepting Patients
nct/study# NCT03651128 / BB2121-MM-003

A Phase 3, Multicenter, Randomized, Open Label Study To Compare The Efficacy And Safety Of BB2121 Versus Standard Triplet Regimens In Subjects With Relapsed And Refractory Multiple Myeloma

Learn More
Multiple Myeloma Phase I Accepting Patients
nct/study# NCT04196491 / BB-2121-MM-004

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, ACTIVEly Diagnosed Multiple Myeloma (KarMMa-4)

Learn More
Multiple Myeloma Phase I/II Accepting Patients
nct/study# NCT02773030 / CC-220-MM-001

A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.